Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
A non-randomized, open-label phase II study to explore the feasibility, time to recurrence,
duration of response and safety of the adjuvant intravesical instillation of EOquin
(apaziquone) in patients with high-risk superficial bladder tumors, and the response and
duration of response in patients with carcinoma in situ of the bladder.